{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:44:38Z","timestamp":1791531878929,"version":"4.3.4"},"reference-count":58,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UM1AI104681"],"award-info":[{"award-number":["UM1AI104681"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,12,20]]},"abstract":"<jats:p>Scant pharmacokinetic (PK) data are available on ceftazidime-avibactam (CZA) and aztreonam (ATM) in combination, and it is unknown if CZA-ATM exacerbates alanine aminotransferase (ALT)\/aspartate aminotransferase (AST) elevations relative to ATM alone. This phase 1 study sought to describe the PK of CZA-ATM and assess the associations between ATM exposures and ALT\/AST elevations.<\/jats:p>","DOI":"10.1128\/aac.00936-22","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T14:01:55Z","timestamp":1668693715000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":22,"title":["Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0655","authenticated-orcid":true,"given":"Thomas P.","family":"Lodise","sequence":"first","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5184-1385","authenticated-orcid":true,"given":"J. Nicholas","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Balevic","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Gu","sequence":"additional","affiliation":[{"name":"Office of Regulatory Affairs (ORA), Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jomy","family":"George","sequence":"additional","affiliation":[{"name":"Office of Regulatory Affairs (ORA), Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0216-1564","authenticated-orcid":true,"given":"Shruti","family":"Raja","sequence":"additional","affiliation":[{"name":"Duke Early Phase Clinical Research Unit, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Guptill","sequence":"additional","affiliation":[{"name":"Duke Early Phase Clinical Research Unit, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Zaharoff","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyssa","family":"Schwager","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8048-0897","authenticated-orcid":false,"suffix":"Jr.","given":"Vance G.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6720-0977","authenticated-orcid":false,"given":"Alison","family":"Wall","sequence":"additional","affiliation":[{"name":"The Emmes Company, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Wiegand","sequence":"additional","affiliation":[{"name":"The Emmes Company, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5317-4491","authenticated-orcid":false,"given":"Henry F.","family":"Chambers","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, and San Francisco General Hospital, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Antibacterial Resistance Leadership Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00472-17"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1222343"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01264.x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx496"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00264-16"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa586"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01008-17"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.05.009"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv132"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02379-15"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02243-16"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00486-17"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa197"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.07.007"},{"key":"e_1_3_3_16_2","unstructured":"Anonymous. 2018. AZACTAM (aztreonam for injection USP). Bristol-Myers Squibb Package Insert. https:\/\/packageinserts.bms.com\/pi\/pi_azactam.pdf."},{"key":"e_1_3_3_17_2","unstructured":"Anonymous. 2020. AVYCAZ (ceftazidime and avibactam) for injection for intravenous use. Package insert. https:\/\/www.allergan.com\/assets\/pdf\/avycaz_pi."},{"key":"e_1_3_3_18_2","volume-title":"LiverTox: clinical and research information on drug-induced liver injury.","author":"Anonymous","year":"2017","unstructured":"Anonymous. 2017. LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548462\/."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv170"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12585"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.810"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0283-9"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01522-06"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.24.3.394"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000238214"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2155-1"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00160"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02309-18"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/653057"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr442"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2019.09.001"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/520991"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.7.1549"},{"key":"e_1_3_3_34_2","unstructured":"Anonymous. 2003. Guidance for industry: exposure-response relationships\u2014study design data analysis and regulatory applications. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Rockville MD. https:\/\/www.fda.gov\/media\/71277\/download."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01184-17"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01945-20"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03684-14"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077075"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/647938"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1086\/376634"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.2948-2953.2000"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02967-15"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1086\/652767"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2012.05.002"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12988"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.215"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.05.029"},{"key":"e_1_3_3_48_2","unstructured":"Anonymous. 2007. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Rockville MD. https:\/\/www.fda.gov\/media\/73679\/download."},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00935-22"},{"key":"e_1_3_3_50_2","unstructured":"Anonymous. 1999. Guidance for industry: population pharmacokinetics. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Rockville MD. https:\/\/www.fda.gov\/media\/71364\/download."},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-013-9526-y"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-009-9112-5"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.131"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000602"},{"key":"e_1_3_3_57_2","volume-title":"Severity grading in drug induced liver injury.","author":"Anonymous","year":"2012","unstructured":"Anonymous. 2012. LiverTox: clinical and research information on drug-induced liver injury. In Severity grading in drug induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD."},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0183-6"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0184-5"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00936-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00936-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T14:10:21Z","timestamp":1671545421000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00936-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,20]]}},"alternative-id":["10.1128\/aac.00936-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.00936-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"assertion":[{"value":"2022-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00936-22"}}